A composite immune signature parallels disease progression across T1D subjects

Cate Speake, Samuel O. Skinner, Dror Berel, Elizabeth Whalen, Matthew J. Dufort, William Chad Young, Jared M. Odegard, Anne M. Pesenacker, Frans K. Gorus, Eddie A. James, Megan K. Levings, Peter S. Linsley, Eitan M. Akirav, Alberto Pugliese, Martin J. Hessner, Gerald T. Nepom, Raphael Gottardo, S. Alice Long

Research output: Contribution to journalArticle

Abstract

At diagnosis, most people with type 1 diabetes (T1D) produce measurable levels of endogenous insulin, but the rate at which insulin secretion declines is heterogeneous. To explain this heterogeneity, we sought to identify a composite signature predictive of insulin secretion, using a collaborative assay evaluation and analysis pipeline that incorporated multiple cellular and serum measures reflecting β cell health and immune system activity. The ability to predict decline in insulin secretion would be useful for patient stratification for clinical trial enrollment or therapeutic selection. Analytes from 12 qualified assays were measured in shared samples from subjects newly diagnosed with T1D. We developed a computational tool (DIFAcTO, Data Integration Flexible to Account for different Types of data and Outcomes) to identify a composite panel associated with decline in insulin secretion over 2 years following diagnosis. DIFAcTO uses multiple filtering steps to reduce data dimensionality, incorporates error estimation techniques including cross-validation and sensitivity analysis, and is flexible to assay type, clinical outcome, and disease setting. Using this novel analytical tool, we identified a panel of immune markers that, in combination, are highly associated with loss of insulin secretion. The methods used here represent a potentially novel process for identifying combined immune signatures that predict outcomes relevant for complex and heterogeneous diseases like T1D.

Original languageEnglish (US)
Article numbere126917
JournalJCI Insight
Volume4
Issue number23
DOIs
StatePublished - Oct 31 2019

Fingerprint

Type 1 Diabetes Mellitus
Disease Progression
Insulin
Immune System
Biomarkers
Clinical Trials
Health
Serum

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Speake, C., Skinner, S. O., Berel, D., Whalen, E., Dufort, M. J., Young, W. C., ... Alice Long, S. (2019). A composite immune signature parallels disease progression across T1D subjects. JCI Insight, 4(23), [e126917]. https://doi.org/10.1172/jci.insight.126917

A composite immune signature parallels disease progression across T1D subjects. / Speake, Cate; Skinner, Samuel O.; Berel, Dror; Whalen, Elizabeth; Dufort, Matthew J.; Young, William Chad; Odegard, Jared M.; Pesenacker, Anne M.; Gorus, Frans K.; James, Eddie A.; Levings, Megan K.; Linsley, Peter S.; Akirav, Eitan M.; Pugliese, Alberto; Hessner, Martin J.; Nepom, Gerald T.; Gottardo, Raphael; Alice Long, S.

In: JCI Insight, Vol. 4, No. 23, e126917, 31.10.2019.

Research output: Contribution to journalArticle

Speake, C, Skinner, SO, Berel, D, Whalen, E, Dufort, MJ, Young, WC, Odegard, JM, Pesenacker, AM, Gorus, FK, James, EA, Levings, MK, Linsley, PS, Akirav, EM, Pugliese, A, Hessner, MJ, Nepom, GT, Gottardo, R & Alice Long, S 2019, 'A composite immune signature parallels disease progression across T1D subjects', JCI Insight, vol. 4, no. 23, e126917. https://doi.org/10.1172/jci.insight.126917
Speake, Cate ; Skinner, Samuel O. ; Berel, Dror ; Whalen, Elizabeth ; Dufort, Matthew J. ; Young, William Chad ; Odegard, Jared M. ; Pesenacker, Anne M. ; Gorus, Frans K. ; James, Eddie A. ; Levings, Megan K. ; Linsley, Peter S. ; Akirav, Eitan M. ; Pugliese, Alberto ; Hessner, Martin J. ; Nepom, Gerald T. ; Gottardo, Raphael ; Alice Long, S. / A composite immune signature parallels disease progression across T1D subjects. In: JCI Insight. 2019 ; Vol. 4, No. 23.
@article{852b7fed54b64d478ec9795d52d9b855,
title = "A composite immune signature parallels disease progression across T1D subjects",
abstract = "At diagnosis, most people with type 1 diabetes (T1D) produce measurable levels of endogenous insulin, but the rate at which insulin secretion declines is heterogeneous. To explain this heterogeneity, we sought to identify a composite signature predictive of insulin secretion, using a collaborative assay evaluation and analysis pipeline that incorporated multiple cellular and serum measures reflecting β cell health and immune system activity. The ability to predict decline in insulin secretion would be useful for patient stratification for clinical trial enrollment or therapeutic selection. Analytes from 12 qualified assays were measured in shared samples from subjects newly diagnosed with T1D. We developed a computational tool (DIFAcTO, Data Integration Flexible to Account for different Types of data and Outcomes) to identify a composite panel associated with decline in insulin secretion over 2 years following diagnosis. DIFAcTO uses multiple filtering steps to reduce data dimensionality, incorporates error estimation techniques including cross-validation and sensitivity analysis, and is flexible to assay type, clinical outcome, and disease setting. Using this novel analytical tool, we identified a panel of immune markers that, in combination, are highly associated with loss of insulin secretion. The methods used here represent a potentially novel process for identifying combined immune signatures that predict outcomes relevant for complex and heterogeneous diseases like T1D.",
author = "Cate Speake and Skinner, {Samuel O.} and Dror Berel and Elizabeth Whalen and Dufort, {Matthew J.} and Young, {William Chad} and Odegard, {Jared M.} and Pesenacker, {Anne M.} and Gorus, {Frans K.} and James, {Eddie A.} and Levings, {Megan K.} and Linsley, {Peter S.} and Akirav, {Eitan M.} and Alberto Pugliese and Hessner, {Martin J.} and Nepom, {Gerald T.} and Raphael Gottardo and {Alice Long}, S.",
year = "2019",
month = "10",
day = "31",
doi = "10.1172/jci.insight.126917",
language = "English (US)",
volume = "4",
journal = "JCI insight",
issn = "2379-3708",
publisher = "The American Society for Clinical Investigation",
number = "23",

}

TY - JOUR

T1 - A composite immune signature parallels disease progression across T1D subjects

AU - Speake, Cate

AU - Skinner, Samuel O.

AU - Berel, Dror

AU - Whalen, Elizabeth

AU - Dufort, Matthew J.

AU - Young, William Chad

AU - Odegard, Jared M.

AU - Pesenacker, Anne M.

AU - Gorus, Frans K.

AU - James, Eddie A.

AU - Levings, Megan K.

AU - Linsley, Peter S.

AU - Akirav, Eitan M.

AU - Pugliese, Alberto

AU - Hessner, Martin J.

AU - Nepom, Gerald T.

AU - Gottardo, Raphael

AU - Alice Long, S.

PY - 2019/10/31

Y1 - 2019/10/31

N2 - At diagnosis, most people with type 1 diabetes (T1D) produce measurable levels of endogenous insulin, but the rate at which insulin secretion declines is heterogeneous. To explain this heterogeneity, we sought to identify a composite signature predictive of insulin secretion, using a collaborative assay evaluation and analysis pipeline that incorporated multiple cellular and serum measures reflecting β cell health and immune system activity. The ability to predict decline in insulin secretion would be useful for patient stratification for clinical trial enrollment or therapeutic selection. Analytes from 12 qualified assays were measured in shared samples from subjects newly diagnosed with T1D. We developed a computational tool (DIFAcTO, Data Integration Flexible to Account for different Types of data and Outcomes) to identify a composite panel associated with decline in insulin secretion over 2 years following diagnosis. DIFAcTO uses multiple filtering steps to reduce data dimensionality, incorporates error estimation techniques including cross-validation and sensitivity analysis, and is flexible to assay type, clinical outcome, and disease setting. Using this novel analytical tool, we identified a panel of immune markers that, in combination, are highly associated with loss of insulin secretion. The methods used here represent a potentially novel process for identifying combined immune signatures that predict outcomes relevant for complex and heterogeneous diseases like T1D.

AB - At diagnosis, most people with type 1 diabetes (T1D) produce measurable levels of endogenous insulin, but the rate at which insulin secretion declines is heterogeneous. To explain this heterogeneity, we sought to identify a composite signature predictive of insulin secretion, using a collaborative assay evaluation and analysis pipeline that incorporated multiple cellular and serum measures reflecting β cell health and immune system activity. The ability to predict decline in insulin secretion would be useful for patient stratification for clinical trial enrollment or therapeutic selection. Analytes from 12 qualified assays were measured in shared samples from subjects newly diagnosed with T1D. We developed a computational tool (DIFAcTO, Data Integration Flexible to Account for different Types of data and Outcomes) to identify a composite panel associated with decline in insulin secretion over 2 years following diagnosis. DIFAcTO uses multiple filtering steps to reduce data dimensionality, incorporates error estimation techniques including cross-validation and sensitivity analysis, and is flexible to assay type, clinical outcome, and disease setting. Using this novel analytical tool, we identified a panel of immune markers that, in combination, are highly associated with loss of insulin secretion. The methods used here represent a potentially novel process for identifying combined immune signatures that predict outcomes relevant for complex and heterogeneous diseases like T1D.

UR - http://www.scopus.com/inward/record.url?scp=85077748478&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85077748478&partnerID=8YFLogxK

U2 - 10.1172/jci.insight.126917

DO - 10.1172/jci.insight.126917

M3 - Article

C2 - 31671072

AN - SCOPUS:85077748478

VL - 4

JO - JCI insight

JF - JCI insight

SN - 2379-3708

IS - 23

M1 - e126917

ER -